$104.44
Value $181B
ABT and TCMD stock compared: price, dividend, valuation and results, from SEC filings.
$104.44
Value $181B
$26.31
Value $590M
Abbott Laboratories (ABT) has a market value of $181B and Tactile Systems Technology (TCMD) $590M. Over the last year, with dividends, ABT moved -17.7% and TCMD +12.2%. The P/E is 38.6 for ABT and 24.8 for TCMD. Dividend yield: ABT 2.41%, TCMD none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABT$181B
TCMD$590M
ABT is 307 times TCMD
Revenue, 12 months
ABT$48.2B
TCMD$356M
ABT is 135 times TCMD
Net income, 12 months
ABT$4.7B
TCMD$24M
ABT is 197 times TCMD
Operating margin
ABT13.8%
TCMD9.4%
4.4 points apart
ROIC
ABT6.3%
TCMD10.2%
3.9 points apart
P/E
ABT38.6
TCMD24.8
ABT is 1.6 times TCMD
Dividend yield
ABT2.4%
TCMD0.0%
2.4 points apart
5-year return
ABT-10.3%
TCMD-1.9%
8.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABT-10.3%
TCMD-1.9%
| Period | ABTWith dividends | TCMDWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | -17.7%Price -19.7% | +12.2%Price +12.2% |
| 3 years since November 17, 2023 | +11.8%+3.8% a yearPrice +4.9% | +128.8%+31.8% a yearPrice +128.8% |
| 5 years since November 17, 2021 | -10.3%-2.1% a yearPrice -18.8% | -1.9%-0.4% a yearPrice -1.9% |
| 10 years since November 18, 2016 | +216.3%+12.2% a yearPrice +162.1% | +42.6%+3.6% a yearPrice +42.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABTAbbott LaboratoriesTCMDTactile Systems Technology
| Price | $104.44 | $26.31 |
|---|---|---|
| Market value | $181B | $590M |
| Enterprise value (EV) | $208B | $515M |
| P/E | 38.6 | 24.8 |
| P/E, 5-year median | 33.7 | 24.5 |
| P/B | 3.6 | 2.6 |
| EV/EBIT | 31.3 | 15.3 |
| Free cash flow yield | 3.7% | 4.9% |
| Revenue, 12 months | $48.2B | $356M |
|---|---|---|
| Net income, 12 months | $4.7B | $24M |
| Free cash flow, 12 months | $6.8B | $29M |
| Earnings per share, 12 months | $2.69 | $1.03 |
| Revenue growth, year on year | 5.7% | 12.5% |
| Revenue growth a year, past | +5.1%over 5 years | +12.0%over 5 years |
| EPS growth a year, past | +8.3%over 5 years | – |
| Gross margin | 56.9% | 77.0% |
|---|---|---|
| Operating margin | 13.8% | 9.4% |
| Net margin | 9.8% | 6.7% |
| ROIC | 6.3% | 10.2% |
| ROE | 9.1% | 10.9% |
| Cash | $4.3B | $75M |
|---|---|---|
| Total debt | $31.2B | $17M |
| Net debt / EBITDA | 3.3 | -1.9 |
| Interest cover | 6.7× | 431.5× |
| Dividend yield | 2.4% | – |
|---|---|---|
| Dividend per share, 12 months | $2.52 | – |
| Dividend growth a year, past | +10.4%over 5 years | – |
| Buyback yield | 0.5% | 4.5% |
| Shareholder yield | 2.9% | 4.5% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Abbott Laboratories ($181B) is about 307.4 times Tactile Systems Technology ($590M), at today's prices.
Since November 18, 2016, ABT's price moved +162.1% and TCMD's +42.6%. With dividends: ABT +216.3% (+12.2% a year), TCMD +42.6% (+3.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.41% for Abbott Laboratories and none for Tactile Systems Technology. Over the last twelve months they paid $2.52 and – per share.
At today's price, the P/E is 38.6 for ABT and 24.8 for TCMD. The median of the last five years was 33.7 and 24.5, which shows where each stands against its own past.
Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 6.7% for Tactile Systems Technology, and the operating margin 13.8% and 9.4%. Revenue was $48.2B and $356M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.